Back to Search
Start Over
Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.
- Source :
-
Sleep medicine [Sleep Med] 2019 Mar; Vol. 55, pp. 74-80. Date of Electronic Publication: 2018 Dec 26. - Publication Year :
- 2019
-
Abstract
- Objectives: To determine whether long-term treatment with dopaminergic agents (DAs) might dampen the response to a non-dopaminergic agent, such as gabapentin enacarbil.<br />Methods: We performed a two-week randomized, double-blind, crossover, and placebo-controlled study in a single, referral center in dopamine treatment-naive patients and non-augmented patients continuously treated with dopaminergics for the last five consecutive years. Following washout from any previous CNS-active drugs, patients were randomized into one of two groups for two consecutive two-week treatment periods with gabapentin enacarbil (GBPen) and placebo. Treatment was administered at 7 PM at a fixed dose of 600 mg/day. RLS severity was measured weekly using the International RLS Scale (IRLS) and Clinical Global Improvement (CGI). An M-SIT was also performed between 6 pm and midnight at the end of each treatment condition.<br />Results: There were no significant differences between groups in age, sex, duration of disease, ferritin levels, RLS severity at baseline, or existing concomitant conditions. Both groups improved more during treatment with GBPen than during placebo on the IRLS scale, CGI and mSIT. However, improvements were greater in the DA-naïve group than in long-term treatment with DAs group on the IRLS (p < 0.05), CGI (p < 0.01), and mSIT (p < 0.01).<br />Conclusions: Previous long-term treatment with DAs reduces future response to GBPen in RLS patients. Potential pathiophysiological explanations are discussed. Our finding has strong implications for the initial choice of treatment in RLS and supports the notion that initial treatment should not be started with DAs.<br />Classification of Evidence: The study provides class II evidence supporting reduced effects of gabapentin enacarbil in RLS patients previously exposed to long-term treatment with dopamine agonists.<br /> (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Aged
Cross-Over Studies
Double-Blind Method
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Restless Legs Syndrome physiopathology
Time Factors
Treatment Outcome
gamma-Aminobutyric Acid administration & dosage
Carbamates administration & dosage
Dopamine Agents administration & dosage
Restless Legs Syndrome diagnosis
Restless Legs Syndrome drug therapy
gamma-Aminobutyric Acid analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1878-5506
- Volume :
- 55
- Database :
- MEDLINE
- Journal :
- Sleep medicine
- Publication Type :
- Academic Journal
- Accession number :
- 30772697
- Full Text :
- https://doi.org/10.1016/j.sleep.2018.11.025